Literature DB >> 32294598

PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells.

Aram Ghalali1, Zhi-Wei Ye2, Johan Högberg3, Ulla Stenius3.   

Abstract

Akt kinase regulates several cellular processes, among them growth, proliferation and survival, and has been correlated to neoplastic disease. We report here crosstalk between several Akt regulatory phosphatases that controls the level of the activated form (phosphorylated) of Akt and affects tumor cell aggressiveness. In prostate cancer cell lines, we observed that transient transfection of PTEN decreased the endogenous level of PHLPPs and in contrast, the transient transfection of PHLPPs decreased the endogenous level of PTEN. Furthermore, silencing of PTEN by siRNA resulted in increased PHLPP levels. This phenomenon was not seen in non-transformed cells or in prostate stem cells. This crosstalk promoted cancer cell invasion and was controlled by epigenetically regulated processes where activation of miRs (miR-190 and miR214), the polycomb group of proteins and DNA methylation were involved. The purinergic P2X4 receptor, which has been shown to have a role in wound healing, was identified to be the mediator of this crosstalk. We also studied prostate stem cells and found this crosstalk in the TGFβ1-activated epithelial-mesenchymal transition (EMT). The crosstalk seemed to be a natural part of EMT. In summary, we identify a crosstalk between Akt phosphatases which is not present in non-transformed prostate cells but occurs in cancer cells and stem cells transformed by TGFβ-1. This crosstalk is important for cellular invasion.
BACKGROUND: Phosphatases regulate the Akt oncogene.
RESULTS: Crosstalk between Akt phosphatases in prostate cancer cells and in TGF-β1 activated stem cells but not in non-transformed cells.
CONCLUSION: This back-up mechanism facilitates invasive migration of prostate stem and cancer cells. SIGNIFICANCE: Characterization of Akt regulation may lead to a better understanding of tumor development and to novel strategies for treatment.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Akt; PHLPP1; PHLPP2; PTEN; Prostate cancer; Stem cells

Mesh:

Substances:

Year:  2020        PMID: 32294598     DOI: 10.1016/j.biopha.2020.110112

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target.

Authors:  Jiepei He; Yuhan Zhou; Hector M Arredondo Carrera; Alexandria Sprules; Ramona Neagu; Sayyed Amin Zarkesh; Colby Eaton; Jian Luo; Alison Gartland; Ning Wang
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

2.  P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.

Authors:  Janielle P Maynard; Jiayun Lu; Igor Vidal; Jessica Hicks; Luke Mummert; Tamirat Ali; Ryan Kempski; Ayanna M Carter; Rebecca Y Sosa; Lauren B Peiffer; Corinne E Joshu; Tamara L Lotan; Angelo M De Marzo; Karen S Sfanos
Journal:  J Pathol       Date:  2021-11-25       Impact factor: 7.996

Review 3.  P2 purinergic receptor dysregulation in urologic disease.

Authors:  Janielle P Maynard; Karen S Sfanos
Journal:  Purinergic Signal       Date:  2022-06-10       Impact factor: 3.950

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.